[心脏β-上腺素受体调节心力衰竭中的线粒体功能]
Ai-Ming Liu1, Wen-Li Xu2, Han Xiao1
1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University; Institute of Advanced Clinical Medicine, Peking University; NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides; Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100191, China.
Sheng li xue bao : [Acta physiologica Sinica]
|January 9, 2025
概括
过度活跃的β-上腺素受体 (β-AR) 在心力衰竭中破坏线粒体功能,导致细胞损伤和代谢问题. 了解这些机制为心力衰竭治疗提供了新的治疗点.
科学领域:
- 心脏病学 心脏病学
- 线粒体生物学 线粒体生物学
- 分子医学是分子医学.
背景情况:
- 心力衰竭涉及异常的β-上腺素受体 (β-AR) 信号和线粒体功能障碍.
- 在心力衰竭中过度激活的β-AR有助于心肌细胞病理,包括氧化应激,过载和代谢异常,导致炎症,亡和亡.
- 线粒体对于能量代谢,平衡,氧化还原平衡和信号传递至关重要,适度的β-AR激活支持它们的功能.
研究的目的:
- 阐明通过β-上腺素受体 (β-AR) 影响线粒体功能的调节机制.
- 调查在交感应激下β-AR过度激活对心力衰竭背景下的氧化应激,亡,亡和代谢失衡的影响.
- 基于对β-AR-线粒体相互作用的全面理解,提出心力衰竭的新型治疗策略.
主要方法:
- 文献综述和对心力衰竭中β-上腺素受体信号传递现有研究的综合.
- 对将β-AR过度激活与线粒体功能障碍联系起来的分子和细胞机制的分析.
- 检查氧化应激,处理和代谢改变在这个过程中的作用.
主要成果:
- 通过各种途径,β-上腺素受体 (β-AR) 的过度激活会破坏心力衰竭中的线粒体平衡.
- 这种干扰加剧了诸如氧化应激,过载和心肌细胞内的代谢失调等病理过程.
- β-AR信号与线粒体功能之间的相互作用是心力衰竭病理学的进展的核心.
结论:
- β-上腺素受体 (β-AR) 过度激活是心力衰竭中线粒体功能障碍的关键驱动因素.
- 准β-AR-线粒体轴为预防和治疗心力衰竭提供了一个有希望的治疗途径.
- 对这些机制的进一步研究可以揭示心力衰竭干预的新目标.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
01:26Heart Failure Drugs: Inotropic Agents
515
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
515
01:29Pathophysiology of Cardiac Performance
530
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
530
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
528
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
528